Evidence map›Paper›PMID 20307256›Full record

ReviewCurrent drug metabolism2010

Update information on drug metabolism systems--2009, part I.

F Peter Guengerich, Slobodan Rendic

Abstract readReview
In one paragraph

Review in Current drug metabolism, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Evaluation ofPharmacogenomics and personalized medicine · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Introduction of anFrontiers in pharmacology · 2016
    Article
  12. Review
  13. Article
  14. Review
  15. Contributions of human enzymes in carcinogen metabolism.Chemical research in toxicology · 2012
    Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

F Peter GuengerichDepartment of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, USA. f.guengerich@vanderbilt.edu
Slobodan Rendic

Funding

Metabolism of Carcinogens and Drugs by Human P450sR37CA090426 · NCI · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2006 to 2015
$3.6M
NCI NIH HHS R37 CA090426
6 · The paper itself

Abstract

The field of drug metabolism has changed dramatically in the past generation. Two of the driving forces are the advances in analytical chemistry and our understanding of the biological systems. With regard to the former, the advances in liquid chromatography-mass spectrometry (LC-MS) are extremely impressive, and the speed of analysis has been increased even more with the recent developments in ultraperformance LC (UPLC). NMR analysis on a sub-microgram scale is not unusual, and the 2-dimensional methods are also very impressive. The biology underlying gene regulation is highly developed, and the recombinant methods have greatly facilitated progress in the field. Today it is common to design discovery and development efforts focused on critical human phenomena from the very start, with animal studies supporting the efficacy and safety efforts.

Indexed as

PharmacokineticsAnimalsBiotransformationCarrier ProteinsCytochrome P-450 Enzyme SystemDrug DesignGenotypeHumansMetabolomicsPharmaceutical PreparationsPhenotypePolymorphism, GeneticSystems BiologySystems IntegrationCarrier ProteinsCytochrome P-450 Enzyme SystemPharmaceutical Preparations

Identifiers

PMID20307256
PMCPMC4755716

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.